Net clinical benefit of anticoagulation therapy in the elderly patients with atrial fibrillation

https://doi.org/10.4081/monaldi.2018.961

Authors

  • Lorenzo Palleschi Hospital S. Giovanni-Addolorata, Unit of Geriatrics, Italy.
  • Eleonora Nunziata | ele.nunziata@gmail.com Unit of Medicine, Asl RM4, Italy.

Abstract

Old age remains one of the strongest risk factors for stroke in patients with atrial fibrillation (AF). Oral anticoagulation (OAC) is the most effective way to prevent thromboembolic disease in patients with atrial fibrillation (AF). Until few years ago, aspirin and vitamin-K antagonists (VKAs) were the primary agents used to prevent thromboembolic disease in patients with AF. The approval of non–vitamin K oral anticoagulants (NOACs) has now expanded the range of therapeutic agents available to providers. The authors highlight practical considerations regarding the selection and use of OAC in older adults to aid clinical decision making.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Downloads

Published
2018-06-07
Info
Issue
Section
Cardiology - Original Articles
Keywords:
Atrial fibrillation, oral anticoagulation, stroke, elderly.
Statistics
  • Abstract views: 2685

  • PDF: 354
How to Cite
Palleschi, Lorenzo, and Eleonora Nunziata. 2018. “Net Clinical Benefit of Anticoagulation Therapy in the Elderly Patients With Atrial Fibrillation”. Monaldi Archives for Chest Disease 88 (2). https://doi.org/10.4081/monaldi.2018.961.

Similar Articles

You may also start an advanced similarity search for this article.